Citi tells investors it’s time to sell Moderna after 600%-plus stock gains

Citi analysts have downgraded Moderna, advising investors to sell the stock after its shares gained more than 600%. The call rests on a valuation gap: in Citi's assessment, the company's revenue and profit forecasts do not justify the price levels reached during the rally. In other words, the market has priced in expectations that the underlying financials, as currently projected, do not yet support.

For readers, the episode illustrates a recurring tension in biotech investing. Vaccine makers can see share prices move sharply on pipeline news, trial data, or shifts in public-health demand, often well ahead of earnings. Analyst ratings like this one are opinions about that gap between narrative and numbers, not verdicts on a company's science or its long-term prospects.

What to watch: upcoming quarterly results, any revisions to revenue guidance, and updates on Moderna's pipeline beyond its COVID-19 products. Those disclosures will test whether forecasts catch up to the valuation — or whether Citi's caution proves warranted.